Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?

Huseyin Kayadibi, Erdim Sertoglu, Metin Uyanik, Serkan Tapan

Red cell distribution width (RDW) may play an important role in predicting steatohepatitis and liver fibrosis. In the original study, it was aimed to determine whether RDW could be used for this purpose or not. There are studies indicating that higher RDW is correlated well with components of metabolic syndrome. Because nonalcoholic fatty liver disease is now recognized as the hepatic manifestation of metabolic syndrome, possible impact of the accompanying confounders on the study findings should have been detailed. There may be a patient selection bias due to use of improper cut-off values for alcohol consumption and inclusion of only subjects with normal aminotransferase levels and normal abdominal ultrasonography. Patients without hepatosteatosis on ultrasonography and with any restriction of aminotransferase levels should have been included in the control group, because isolated aminotransferase elevation is not decisive in the diagnosis of hepatosteatosis. Although iron, vitamin B\textsubscript{12} and folic acid deficiencies were included in exclusion criteria, functional forms of these molecules like methylmalonic acid, homocysteine, ferritin levels and total iron binding capacity, which are more sensitive and specific parameters for vitamin B\textsubscript{12} and folic acid deficiencies, were not mentioned. Consequently, RDW itself without other inflammatory markers may not accurately provide information about progression of nonalcoholic steatohepatitis and fibrosis.
by Cengiz et al.[4], “Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?”. In this study, authors have evaluated red cell distribution width (RDW) as a marker indicating nonalcoholic steatohepatitis (NASH) and fibrotic stage, and as a conclusion, RDW was reported as a new non-invasive marker that can be used to demonstrate the presence of NASH and to indicate advanced fibrotic scores. There are some points that we would like to address from this study.

Firstly, in that study, it was stated that 30.6% of the patients with NASH had diabetes mellitus (DM) and 35.4% of those had hypertension (HT). As is well known, DM and HT are the two of five diagnostic criteria for metabolic syndrome (MetS) determined by the National Cholesterol Education Program Adult Treatment Panel III[5]. There are studies indicating that higher RDW is correlated with hypertension[6]. Moreover, high level of RDW was also associated with the MetS, leading to postulation of a possible effect of an underlying inflammatory state which typically occurred in DM and MetS on increased destruction of erythrocytes[6]. Because NAFLD is now recognized as the hepatic manifestation of MetS, the possible impact of the accompanying confounders on the study findings should have been detailed.

Secondly, all the patients who had persistently elevated liver enzymes and hepatosteatosis on ultrasonography, in the absence of any cause of elevated aminotransferases, were evaluated in the original study. The control group was created among individuals who had normal aminotransferase levels and normal abdominal ultrasonography. However, patients without hepatosteatosis on ultrasonography and with any restriction of aminotransferase levels should have been included in the control group, because isolated aminotransferase elevation is not decisive in the diagnosis of hepatosteatosis. According to these selection criteria, it is obvious that there is a patient selection bias for aminotransferase levels. Another patient selection bias is derived from the selected cut-offs for the alcohol consumption value. In that study, alcohol consumption > 20 g/d for men and > 10 g/d for women was accepted as exclusion criteria. However, it is generally accepted as > 30 g/d for men and > 20 g/d for women[8]. Therefore, misuse of this cut-off value could have led more patients to be included into the original study.

Thirdly, although iron, vitamin B12 and folic acid deficiencies were included in exclusion criteria, functional forms of these molecules like methyl malonic acid, homocysteine, ferritin levels and total iron binding capacity were not mentioned; however, active forms of these vitamins, methyl malonic acid and homocysteine levels are more sensitive and specific parameters for vitamin B12 and folic acid deficiencies. Since RDW is directly related to these deficiencies, this situation makes an accuracy bias[6,7]. Consequently, RDW, an inexpensive, non-invasive, but powerful indicator overlooked on whole blood analysis, itself without other inflammatory markers may not accurately provide information about progression of NASH and fibrosis. So, we think that, when evaluating any marker associated with inflammation in patients with NASH, the effects of confounders like DM and HT should also be discussed in detail. In addition, factors affecting the RDW results like iron, vitamin B12 and folic acid deficiency should be considered to conclude that RDW is a useful diagnostic tool to discriminate patients with NASH from non-NASH, and advanced fibrosis from non-advanced fibrosis. In this way, further information can be obtained about the association between RDW and NASH.

REFERENCES

1. Cengiz M, Candir BA, Yılmaz G, Akyol G, Ozenirler S. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage? World J Gastroenterol 2013; 19: 7412-7418 [PMID: 24259972 DOI: 10.3748/wjg.v19.i42.7412]

2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497 [PMID: 11368702 DOI: 10.1001/jama.285.19.2486]

3. Ozcan F, Turak O, Durak A, İşleyen A, Uçar F, Giniş Z, Uçar F, Başar FN, Aydoğdu S. Red cell distribution width and inflammation in patients with non-dipper hypertension. Blood Press 2013; 22: 80-85 [PMID: 22835009 DOI: 10.3109/08030705.1.2012.707336]

4. Sánchez-Chaparro MA, Calvo-Bonacho E, Gonzalez-Quintela A, Cabrera M, Sáinz JC, Fernández-Labandera C, Aguado LQ, Meseguer AF, Valdiviezo P, Román-García J. Higher red blood cell distribution width and inflammation in patients with non-dipper hypertension. Blood Press 2013; 22: 80-85 [PMID: 22835009 DOI: 10.3109/08030705.1.2012.707336]

5. Chalasani N, Younossi Z, Lavinje JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guidelines by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]

6. Tefferi A. Anemia in adults: a contemporary approach to diagnosis. Mayo Clin Proc 2003; 78: 1274-1280 [PMID: 14531486 DOI: 10.4065/78.10.1274]

7. Hultberg B, Isaksson A, Nilsson K, Gustafson L. Markers for the functional availability of cobalamin/folate and their association with neuropsychiatric symptoms in the elderly. Int J Geriatr Psychiatry 2001; 16: 873-878 [PMID: 11571767 DOI: 10.1002/gps.439]
